<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
<channel>
<title>Lexeo Therapeutics, Inc. Common Stock — News on 6ix</title>
<link>https://6ix.com/company/lexeo-therapeutics-inc-common-stock</link>
<description>Latest news and press releases for Lexeo Therapeutics, Inc. Common Stock on 6ix.</description>
<language>en-us</language>
<lastBuildDate>Mon, 27 Apr 2026 21:15:00 GMT</lastBuildDate>
<generator>6ix RSS</generator>
<atom:link href="https://6ix.com/rss/company/lexeo-therapeutics-inc-common-stock" rel="self" type="application/rss+xml" />
<image>
<url>https://6ix-events-pro.s3.amazonaws.com/6ixvideo/logos/org-logo683594d678dffbe2df103e25.webp</url>
<title>Lexeo Therapeutics, Inc. Common Stock</title>
<link>https://6ix.com/company/lexeo-therapeutics-inc-common-stock</link>
</image>
<item>
<title>Lexeo Therapeutics Announces Multiple Presentations at the 29th American Society of Gene & Cell Therapy (ASGCT) Annual Meeting</title>
<link>https://6ix.com/company/lexeo-therapeutics-inc-common-stock/news/lexeo-therapeutics-announces-multiple-presentations-at-the-29th-american-society-of-gene-and-cell-therapy-asgct-annual-meeting</link>
<guid isPermaLink="true">https://6ix.com/company/lexeo-therapeutics-inc-common-stock/news/lexeo-therapeutics-announces-multiple-presentations-at-the-29th-american-society-of-gene-and-cell-therapy-asgct-annual-meeting</guid>
<pubDate>Mon, 27 Apr 2026 21:15:00 GMT</pubDate>
<description>Oral and poster presentations highlight progress across cardiac genetic medicine pipeline and optimized, Sf9-baculovirus AAV manufacturing platformNEW YORK, April 27, 2026 (GLOBE NEWSWIRE) -- Lexeo Therapeutics, Inc. (Nasdaq: LXEO), a clinical stage genetic medicine company dedicated to pioneering novel treatments for cardiovascular diseases, announced today that new data supporting its cardiac gene therapy programs and optimized AAV manufacturing approach will be presented at the 29th Annual Me</description>
</item>
<item>
<title>Lexeo Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Operational Highlights</title>
<link>https://6ix.com/company/lexeo-therapeutics-inc-common-stock/news/lexeo-therapeutics-reports-fourth-quarter-and-full-year-2025-financial-results-and-operational-highlights</link>
<guid isPermaLink="true">https://6ix.com/company/lexeo-therapeutics-inc-common-stock/news/lexeo-therapeutics-reports-fourth-quarter-and-full-year-2025-financial-results-and-operational-highlights</guid>
<pubDate>Mon, 30 Mar 2026 04:00:00 GMT</pubDate>
<description>SUNRISE-FA 2 open-label, pivotal trial protocol and SAP for LX2006 submitted to FDA in Q1 2026 following Type B meeting; study initiation on track for 1H 2026</description>
</item>
<item>
<title>Lexeo Therapeutics to Participate in the Leerink Global Healthcare Conference</title>
<link>https://6ix.com/company/lexeo-therapeutics-inc-common-stock/news/lexeo-therapeutics-to-participate-in-the-leerink-global-healthcare-conference</link>
<guid isPermaLink="true">https://6ix.com/company/lexeo-therapeutics-inc-common-stock/news/lexeo-therapeutics-to-participate-in-the-leerink-global-healthcare-conference</guid>
<pubDate>Tue, 03 Mar 2026 12:30:00 GMT</pubDate>
<description>NEW YORK, March 03, 2026 (GLOBE NEWSWIRE) -- Lexeo Therapeutics, Inc. (Nasdaq: LXEO), a clinical stage genetic medicine company dedicated to pioneering novel treatments for cardiovascular diseases, today announced that the Company will participate in a fireside chat at the Leerink Global Healthcare Conference on Tuesday, March 10, 2026 at 10:00 a.m. ET in Miami, FL. The event will be webcast live under the News & Events tab in the Investors section of the Company’s website. A replay of the webca</description>
</item>
<item>
<title>Lexeo Therapeutics to Participate in Upcoming Investor Conferences in February</title>
<link>https://6ix.com/company/lexeo-therapeutics-inc-common-stock/news/lexeo-therapeutics-participate-upcoming-investor-123000491</link>
<guid isPermaLink="true">https://6ix.com/company/lexeo-therapeutics-inc-common-stock/news/lexeo-therapeutics-participate-upcoming-investor-123000491</guid>
<pubDate>Thu, 05 Feb 2026 12:30:00 GMT</pubDate>
<description>NEW YORK, Feb. 05, 2026 (GLOBE NEWSWIRE) -- Lexeo Therapeutics, Inc. (Nasdaq: LXEO), a clinical stage genetic medicine company dedicated to pioneering novel treatments for cardiovascular diseases, today announced that members of management will participate in the following investor conferences in February: Guggenheim Emerging Outlook: Biotech Summit 2026. Fireside chat on Thursday, February 12, 2026 at 12:30 p.m. ET in New York, NY. Oppenheimer 36th Annual Healthcare Life Sciences Conference. Fi</description>
</item>
<item>
<title>Lexeo Therapeutics Announces Key Leadership Appointments Strengthening Cardiovascular Expertise Alongside Updates to Strategic Partnership for Novel Cardiac RNA Therapeutics</title>
<link>https://6ix.com/company/lexeo-therapeutics-inc-common-stock/news/lexeo-therapeutics-announces-key-leadership-123000764</link>
<guid isPermaLink="true">https://6ix.com/company/lexeo-therapeutics-inc-common-stock/news/lexeo-therapeutics-announces-key-leadership-123000764</guid>
<pubDate>Tue, 27 Jan 2026 12:30:00 GMT</pubDate>
<description>NEW YORK, Jan. 27, 2026 (GLOBE NEWSWIRE) -- Lexeo Therapeutics, Inc. (Nasdaq: LXEO), a clinical stage genetic medicine company dedicated to pioneering novel treatments for cardiovascular diseases, today announced a series of key senior leadership appointments that underscore the company’s continued and growing expertise in cardiovascular medicine and late-stage clinical development. The company also provided an update on the strategic partnership announced in June 2025 with Perceptive Xontogeny</description>
</item>
<item>
<title>Lexeo Therapeutics Announces Positive Interim Phase I/II Data for LX2020 for the Treatment of PKP2-Associated Arrhythmogenic Cardiomyopathy</title>
<link>https://6ix.com/company/lexeo-therapeutics-inc-common-stock/news/lexeo-therapeutics-announces-positive-interim-120000126</link>
<guid isPermaLink="true">https://6ix.com/company/lexeo-therapeutics-inc-common-stock/news/lexeo-therapeutics-announces-positive-interim-120000126</guid>
<pubDate>Mon, 12 Jan 2026 12:00:00 GMT</pubDate>
<description>LX2020 generally well tolerated across ten participants with no clinically significant complement activation LX2020 transduction, transcription, and increased protein expression observed across participants with dose-dependent response; mean increase in PKP2 protein of 93% in low-dose cohort and 162% in high-dose cohorts Arrhythmia burden stabilized or improved in majority of participants with dose-dependent response in non-sustained ventricular tachycardia and premature ventricular contractions</description>
</item>
<item>
<title>Lexeo Therapeutics Announces Research Collaboration to Explore Targeted Cardiac Delivery of AAV Gene Therapy</title>
<link>https://6ix.com/company/lexeo-therapeutics-inc-common-stock/news/lexeo-therapeutics-announces-research-collaboration-120000870</link>
<guid isPermaLink="true">https://6ix.com/company/lexeo-therapeutics-inc-common-stock/news/lexeo-therapeutics-announces-research-collaboration-120000870</guid>
<pubDate>Thu, 08 Jan 2026 12:00:00 GMT</pubDate>
<description>Collaboration will combine Lexeo expertise in cardiac genetic medicine with Johnson & Johnson’s expertise in cardiovascular therapeutics and circulatory technologies, including Impella™ heart pumps Agreement will enable accelerated development of a preclinical cardiac target using novel, localized routes of viral gene therapy administration NEW YORK, Jan. 08, 2026 (GLOBE NEWSWIRE) -- Lexeo Therapeutics, Inc. (Nasdaq: LXEO), a clinical stage genetic medicine company dedicated to pioneering novel</description>
</item>
<item>
<title>Lexeo Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference</title>
<link>https://6ix.com/company/lexeo-therapeutics-inc-common-stock/news/lexeo-therapeutics-present-44th-annual-123000269</link>
<guid isPermaLink="true">https://6ix.com/company/lexeo-therapeutics-inc-common-stock/news/lexeo-therapeutics-present-44th-annual-123000269</guid>
<pubDate>Mon, 22 Dec 2025 12:30:00 GMT</pubDate>
<description>NEW YORK, Dec. 22, 2025 (GLOBE NEWSWIRE) -- Lexeo Therapeutics, Inc. (Nasdaq: LXEO), a clinical stage genetic medicine company dedicated to pioneering novel treatments for cardiovascular diseases, today announced that R. Nolan Townsend, Chief Executive Officer of Lexeo Therapeutics, will present at the 44th Annual J.P. Morgan Healthcare Conference on Wednesday, January 14, 2026, at 7:30 AM PT in San Francisco, California. The event will be webcast live under the News & Events tab in the Investor</description>
</item>
<item>
<title>Lexeo Therapeutics to Host Virtual Key Opinion Leader Event at the 22nd Global Cardiovascular Clinical Trialists (CVCT) Forum</title>
<link>https://6ix.com/company/lexeo-therapeutics-inc-common-stock/news/lexeo-therapeutics-host-virtual-key-130000296</link>
<guid isPermaLink="true">https://6ix.com/company/lexeo-therapeutics-inc-common-stock/news/lexeo-therapeutics-host-virtual-key-130000296</guid>
<pubDate>Thu, 04 Dec 2025 13:00:00 GMT</pubDate>
<description>NEW YORK, Dec. 04, 2025 (GLOBE NEWSWIRE) -- Lexeo Therapeutics, Inc. (Nasdaq: LXEO), a clinical stage genetic medicine company dedicated to pioneering novel treatments for cardiovascular diseases, today announced plans to host a virtual event, “A Clinician’s Perspective: Holistic Approach to Managing PKP2-Associated Arrhythmogenic Cardiomyopathy,” at the 22nd Global Cardiovascular Clinical Trialists (CVCT) Forum on Tuesday, December 9th at 3 PM ET. The session will feature a discussion with Dr.</description>
</item>
<item>
<title>Lexeo Therapeutics Reports Third Quarter 2025 Financial Results and Operational Highlights</title>
<link>https://6ix.com/company/lexeo-therapeutics-inc-common-stock/news/lexeo-therapeutics-reports-third-quarter-123600132</link>
<guid isPermaLink="true">https://6ix.com/company/lexeo-therapeutics-inc-common-stock/news/lexeo-therapeutics-reports-third-quarter-123600132</guid>
<pubDate>Wed, 05 Nov 2025 12:36:00 GMT</pubDate>
<description>FDA open to pooling data from ongoing Phase I/II studies of LX2006 with data from pivotal trial, and to earlier co-primary endpoint assessment, to support a Biologics License Application FDA approved comparability report between LX2006 HEK and Sf9 manufacturing processes in November 2025, endorsing use of Sf9 final commercial manufacturing process to begin dosing patients in upcoming pivotal study LX2006 interim clinical data show clinically meaningful improvements across cardiac and neurologic</description>
</item>
<item>
<title>Lexeo Therapeutics Announces Closing of Public Offering and Concurrent Private Placement and Exercise in Full of the Underwriters’ Option to Purchase Additional Shares in the Public Offering</title>
<link>https://6ix.com/company/lexeo-therapeutics-inc-common-stock/news/lexeo-therapeutics-announces-closing-public-200500768</link>
<guid isPermaLink="true">https://6ix.com/company/lexeo-therapeutics-inc-common-stock/news/lexeo-therapeutics-announces-closing-public-200500768</guid>
<pubDate>Mon, 20 Oct 2025 20:05:00 GMT</pubDate>
<description>NEW YORK, Oct. 20, 2025 (GLOBE NEWSWIRE) -- Lexeo Therapeutics, Inc. (Nasdaq: LXEO) (“Lexeo”), a clinical stage genetic medicine company dedicated to pioneering novel treatments for cardiovascular diseases, today announced the closing of its previously announced underwritten public offering and concurrent private placement, for total gross proceeds to Lexeo of approximately $153.8 million, before deducting underwriting discounts and commission and other expenses payable by Lexeo in connection wi</description>
</item>
<item>
<title>Lexeo Therapeutics Announces Pricing of Public Offering and Concurrent Private Placement</title>
<link>https://6ix.com/company/lexeo-therapeutics-inc-common-stock/news/lexeo-therapeutics-announces-pricing-public-032900214</link>
<guid isPermaLink="true">https://6ix.com/company/lexeo-therapeutics-inc-common-stock/news/lexeo-therapeutics-announces-pricing-public-032900214</guid>
<pubDate>Fri, 17 Oct 2025 03:29:00 GMT</pubDate>
<description>NEW YORK, Oct. 16, 2025 (GLOBE NEWSWIRE) -- Lexeo Therapeutics, Inc. (Nasdaq: LXEO), a clinical stage genetic medicine company dedicated to pioneering novel treatments for cardiovascular diseases, today announced that it has priced its underwritten public offering and concurrent private placement for gross proceeds to Lexeo of approximately $135 million, before deducting underwriting discounts and commissions and other expenses payable by Lexeo in connection with the transactions and excluding a</description>
</item>
<item>
<title>Lexeo Therapeutics Announces Proposed Offering of Common Stock and Pre-Funded Warrants</title>
<link>https://6ix.com/company/lexeo-therapeutics-inc-common-stock/news/lexeo-therapeutics-announces-proposed-offering-203200829</link>
<guid isPermaLink="true">https://6ix.com/company/lexeo-therapeutics-inc-common-stock/news/lexeo-therapeutics-announces-proposed-offering-203200829</guid>
<pubDate>Thu, 16 Oct 2025 20:32:00 GMT</pubDate>
<description>NEW YORK, Oct. 16, 2025 (GLOBE NEWSWIRE) -- Lexeo Therapeutics, Inc. (Nasdaq: LXEO) (the “Lexeo”), a clinical stage genetic medicine company dedicated to pioneering novel treatments for cardiovascular diseases, today announced that it has commenced an underwritten public offering and concurrent private placement of shares of its common stock and, in lieu of common stock to certain investors, pre-funded warrants to purchase shares of its common stock. In addition, Lexeo intends to grant the under</description>
</item>
<item>
<title>Lexeo Therapeutics Announces Progress in FDA Discussions for Accelerated Approval Pathway and Positive Interim Clinical Data for LX2006 in Friedreich Ataxia Cardiomyopathy</title>
<link>https://6ix.com/company/lexeo-therapeutics-inc-common-stock/news/lexeo-therapeutics-announces-progress-fda-100000849</link>
<guid isPermaLink="true">https://6ix.com/company/lexeo-therapeutics-inc-common-stock/news/lexeo-therapeutics-announces-progress-fda-100000849</guid>
<pubDate>Tue, 07 Oct 2025 10:00:00 GMT</pubDate>
<description>U.S. Food and Drug Administration (FDA) open to pooling data from ongoing Phase I/II studies of LX2006 with pivotal data to support a Biologics License Application (BLA) for Accelerated Approval Interim clinical data show sustained or deepening improvements in the majority of participants across both cardiac and neurologic measures of Friedreich ataxia Participants with abnormal left ventricular mass index (LVMI) at baseline achieved 18% mean reduction in LVMI at 6 months and 23% mean reduction</description>
</item>
<item>
<title>Lexeo Therapeutics Reports Second Quarter 2025 Financial Results and Operational Highlights</title>
<link>https://6ix.com/company/lexeo-therapeutics-inc-common-stock/news/lexeo-therapeutics-reports-second-quarter-113000603</link>
<guid isPermaLink="true">https://6ix.com/company/lexeo-therapeutics-inc-common-stock/news/lexeo-therapeutics-reports-second-quarter-113000603</guid>
<pubDate>Thu, 14 Aug 2025 11:30:00 GMT</pubDate>
<description>Breakthrough Therapy designation granted for LX2006 based on interim data from Phase I/II trials demonstrating clinically meaningful improvements in cardiac and neurologic measures of Friedreich ataxia LX2006 selected for FDA Chemistry, Manufacturing, and Controls Development and Readiness Pilot (CDRP) program, created to facilitate CMC registrational readiness and support faster patient access Eight participants dosed in Phase I/II clinical trial (HEROIC-PKP2) of LX2020 for PKP2-ACM; interim cl</description>
</item>
<item>
<title>Lexeo Therapeutics Announces FDA Breakthrough Therapy Designation for LX2006 in Friedreich Ataxia</title>
<link>https://6ix.com/company/lexeo-therapeutics-inc-common-stock/news/lexeo-therapeutics-announces-fda-breakthrough-110000430</link>
<guid isPermaLink="true">https://6ix.com/company/lexeo-therapeutics-inc-common-stock/news/lexeo-therapeutics-announces-fda-breakthrough-110000430</guid>
<pubDate>Mon, 07 Jul 2025 11:00:00 GMT</pubDate>
<description>Breakthrough Therapy designation based on interim clinical data from Phase I/II trials showing clinically meaningful improvements in cardiac biomarkers and functional measures LX2006 also selected for FDA Chemistry, Manufacturing, and Controls Development and Readiness Pilot (CDRP) program, created to facilitate CMC registrational readiness and support faster patient access NEW YORK, July 07, 2025 (GLOBE NEWSWIRE) -- Lexeo Therapeutics, Inc. (Nasdaq: LXEO), a clinical stage genetic medicine comp</description>
</item>
<item>
<title>Lexeo Therapeutics, Perceptive Xontogeny Venture Funds and venBio Partners Announce Partnership to Advance Novel Cardiac RNA Therapeutics</title>
<link>https://6ix.com/company/lexeo-therapeutics-inc-common-stock/news/lexeo-therapeutics-perceptive-xontogeny-venture-113000810</link>
<guid isPermaLink="true">https://6ix.com/company/lexeo-therapeutics-inc-common-stock/news/lexeo-therapeutics-perceptive-xontogeny-venture-113000810</guid>
<pubDate>Tue, 24 Jun 2025 11:30:00 GMT</pubDate>
<description>Up to $40 Million Private Equity Financing into a New Entity Addressing Cardiac Genetic Diseases that Existing AAV Platforms are Unable to Treat Lexeo Contributing Expertise and Know-How in Cardiac Genetic Medicines, Preclinical Intellectual Property, and Technology, in Combination with Novel Non-Viral RNA Delivery Platform Represents Pipeline Diversification and Advancement of Leading-Edge Cardiovascular Science NEW YORK, June 24, 2025 (GLOBE NEWSWIRE) -- Lexeo Therapeutics, Inc. (Nasdaq: LXEO)</description>
</item>
<item>
<title>Lexeo Therapeutics Announces $80 Million Equity Financing to Further Advance Development of Transformative Genetic Medicines for Cardiovascular Diseases</title>
<link>https://6ix.com/company/lexeo-therapeutics-inc-common-stock/news/lexeo-therapeutics-announces-80-million-113100634</link>
<guid isPermaLink="true">https://6ix.com/company/lexeo-therapeutics-inc-common-stock/news/lexeo-therapeutics-announces-80-million-113100634</guid>
<pubDate>Tue, 27 May 2025 11:31:00 GMT</pubDate>
<description>Cash runway extended into 2028; capital proceeds to fund operations through potential 2027 efficacy readout for LX2006 in Friedreich ataxia cardiomyopathy Financing led by Frazier Life Sciences and Janus Henderson Investors with participation from new and existing investors NEW YORK, May 27, 2025 (GLOBE NEWSWIRE) -- Lexeo Therapeutics, Inc. (Nasdaq: LXEO), a clinical stage genetic medicine company dedicated to pioneering novel treatments for cardiovascular diseases, today announced it has entere</description>
</item>
<item>
<title>Lexeo Therapeutics Reports First Quarter 2025 Financial Results and Operational Highlights</title>
<link>https://6ix.com/company/lexeo-therapeutics-inc-common-stock/news/lexeo-therapeutics-reports-first-quarter-110000412</link>
<guid isPermaLink="true">https://6ix.com/company/lexeo-therapeutics-inc-common-stock/news/lexeo-therapeutics-reports-first-quarter-110000412</guid>
<pubDate>Mon, 12 May 2025 11:00:00 GMT</pubDate>
<description>Announced positive interim data for LX2006 from Phase 1/2 studies in Friederich ataxia (FA) cardiomyopathy; frataxin expression and LVMI improvement exceeded co-primary target thresholds for planned registrational study LX2006 registrational study expected to begin by early 2026; commencing enrollment in prospective natural history study, CLARITY-FA, in Q2 2025 to serve as concurrent external control Phase 1/2 clinical trial of LX2020 (HEROIC-PKP2) currently enrolling patients in Cohort 3; inter</description>
</item>
<item>
<title>Lexeo Therapeutics to Present New CMC Data at the 28th American Society of Gene & Cell Therapy (ASGCT) Annual Meeting</title>
<link>https://6ix.com/company/lexeo-therapeutics-inc-common-stock/news/lexeo-therapeutics-present-cmc-data-131600872</link>
<guid isPermaLink="true">https://6ix.com/company/lexeo-therapeutics-inc-common-stock/news/lexeo-therapeutics-present-cmc-data-131600872</guid>
<pubDate>Thu, 01 May 2025 13:16:00 GMT</pubDate>
<description>Research highlights AAV manufacturing optimization via Lexeo’s Sf9-baculovirus processNEW YORK, May 01, 2025 (GLOBE NEWSWIRE) -- Lexeo Therapeutics, Inc. (Nasdaq: LXEO), a clinical stage genetic medicine company dedicated to pioneering novel treatments for cardiovascular diseases, announced today that new data supporting its AAV manufacturing approach will be presented at the 28th Annual Meeting of the American Society of Gene & Cell Therapy (ASGCT) taking place May 13-17, 2025 in New Orleans, L</description>
</item>
</channel>
</rss>